Complications of oral antiplatelet medications

被引：2

作者：

Van De Graaff E. ^{[1
]}

Steinhubl S.R. ^{[1
]}

机构：

[1] Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236

来源：

Current Cardiology Reports | 2001年 / 3卷 / 5期

关键词：

Aspirin; Clopidogrel; Dipyridamole; Ticlopidine; Thrombotic Thrombocytopenic Purpura;

D O I：

10.1007/s11886-001-0053-6

中图分类号：

学科分类号：

摘要：

One by-product of the flurry of large-scale clinical trials accompanying the emergence of drugs that inhibit platelet function is volumes of information chronicling the adverse effects of this class of medications. One aspect all antiplatelet drugs share is a propensity toward bleeding. Beyond that similarity, however, the different pharmacologic agents in this broad collection have few attributes in common. Aspirin, by virtue of its long history, has been studied most extensively, and has proven to be an exceptionally valuable therapy. However, the complicated adverse profile of this seemingly simple drug is commonly overlooked by practitioners and deserves clinical review. The thienopyridine class (including ticlopidine and clopidogrel) share certain peculiarities that continue to be clarified, including life-threatening thrombotic thrombocytopenia purpura. Dipyridamole is a veteran drug that is enjoying renewed attention as a prophylactic aid in preventing cerebrovascular events. One class, the oral platelet glycoprotein IIb/IIIa receptor inhibitors, has failed to find its way into clinical implementation due to an unfavorable balance between efficacy and adverse effect. This review summarizes the adverse profiles of each of these drug classes and draws on data gathered in large clinical studies. Copyright © 2001 by Current Science Inc..

引用

页码：371 / 379

页数：8

共 38 条

[1]

McLeod L., Roberts M., Cossum P., Vial J., The effects of different doses of some acetyl salicylic acid formulations on platelet function and bleeding times in healthy subjects, Scand J Haematol, 36, pp. 379-384, (1986)

[2]

Collaborative overview of randomised trials of antiplatelet therapy-i. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, Br Med J, 308, pp. 81-106, (1994)

[3]

Graham D., Smith J., Dobbs S., Gastric adaptation occurs with aspirin administration in man, Dig Dis Scit, 28, pp. 1-6, (1983)

[4]

Cooke A., The role of acid in the pathogenesis of aspirin-induced gastrointestinal erosions and hemorrhage, Am J Dig Dis, 18, pp. 225-237, (1973)

[5]

Hawkey C., Hawthorne A., Hudson N., Et al., Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach, Clin Sci, 81, pp. 565-573, (1991)

[6]

Lanza F., Royer G.J., Nelson R., Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa, N Engl J Med, 303, pp. 136-138, (1980)

[7]

Kelly J., Kaufman D., Jurgelon J., Et al., Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product, Lancet, 348, pp. 1413-1416, (1996)

[8]

Roderick P., Wilkes H., Meade T., The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials, Br J Clinc Pharmac, 35, pp. 219-226, (1993)

[9]

Swedish aspirin low-dose trial (salt) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events, Lancet, 338, pp. 1345-1349, (1991)

[10]

Slattery J., Warlow C., Shorrock C., Langman M., Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the uk-tia trial, Gut, 37, pp. 509-511, (1995)

← 1 2 3 4 →